

CADTH RAPID RESPONSE REPORT: SUMMARY OF ABSTRACTS

# Sample Selection for Biomarker Testing in Adults with Breast Cancer: Guidelines

Service Line: Rapid Response Service  
Version: 1.0  
Publication Date: February 6, 2019  
Report Length: 7 Pages

**Authors:** Deba Hafizi, Hannah Loshak

**Cite As:** Sample selection for biomarker testing in adults with breast cancer: guidelines. Ottawa: CADTH; 2019 Jan. (CADTH rapid response report: summary of abstracts).

**Disclaimer:** The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

**About CADTH:** CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

**Funding:** CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

## Research Question

What are the evidence-based guidelines regarding sample selection for biomarker testing to inform treatment decisions in adults with breast cancer?

## Key Findings

Four evidence-based guidelines were identified regarding sample selection for biomarker testing in adults with breast cancer.

## Methods

A limited literature search was conducted on key resources including Medline via OVID, the Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. Methodological filters were applied to limit retrieval to health technology assessments, systematic reviews, meta-analyses, and guidelines. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2014 and January 28, 2019. Internet links were provided, where available.

## Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

**Table 1: Selection Criteria**

<b>Population</b>	Adult patients with breast cancer
<b>Intervention</b>	Biomarker testing (i.e., ER/PR, and HER2) on core biopsy or definitive tumour samples
<b>Comparator</b>	No comparator
<b>Outcomes</b>	Evidence-based guidelines
<b>Study Designs</b>	Health technology assessments, systematic reviews, meta-analyses, evidence-based guidelines

## Results

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by evidence-based guidelines.

Four evidence-based guidelines were identified regarding sample selection for biomarker testing in adults with breast cancer. No relevant health technology assessments, systematic reviews, or meta-analyses were identified.

Additional references of potential interest are provided in the appendix.

## Overall Summary of Findings

Four evidence-based guidelines were identified regarding sample selection for biomarker testing in adults with breast cancer.<sup>1-4</sup> The first guideline from the National Institute of Health and Care Excellence (NICE)<sup>1</sup> recommends that the status of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth receptor 2 (HER2) of all invasive breast cancers should be simultaneously checked at the time of initial histopathological diagnosis using standardized and quality-assured immunohistochemical techniques. They also recommend ER, PR, and HER2 status be recorded at the pre- and postoperative multidisciplinary team meetings when systemic treatment is discussed.<sup>1</sup>

Another guideline from NICE<sup>2</sup> recommends using tumour profiling tests including EndoPredict, Oncotype DX Breast Recurrence Score, and Prosigna as options for guiding adjuvant chemotherapy decisions for people with ER-positive, HER2-negative, and lymph-node (LN)-negative early breast cancer. These are only recommended if the patient has an intermediate risk of distant recurrence. The tests would help with the decision to pursue adjuvant therapy while taking into consideration the patient's preferences for treatment.<sup>2</sup> The tumour profiling test MammaPrint is not recommended for guiding adjuvant chemotherapy decisions in patients with the aforementioned biomarker profile because it is not cost effective; IHC4+C is also not recommended because the analytical validity of the test is uncertain.<sup>2</sup>

The American Society of Breast Surgeons (ASBrS) created an evidence-based guideline of neoadjuvant systemic therapy (NST). They included the following recommendations in the care of patients with breast cancer: "... (2) minimally invasive biopsies of breast and axillary lesions; (3) determination of tumor biomarkers; (4) systemic staging;... (6) initiation of NST; (7) post-NST breast and axillary imaging; and (8) decision for surgery based on extent of disease at presentation, patient choice, clinical response to NST, and genetic testing results, if performed."<sup>3</sup>

The guideline by the American Society of Clinical Oncology/College of American Pathologists provided recommendations on HER2 testing in breast cancer.<sup>4</sup> They recommend that, "HER2 status (HER2 negative or positive) be determined in all patients with invasive (early stage or recurrence) breast cancer on the basis of one or more HER2 test results (negative, equivocal, or positive)."<sup>4</sup> Reflex testing should be performed if results are equivocal by using an alternative assay such as immunohistochemistry or in situ hybridization.<sup>4</sup> Lastly, "repeat testing should be considered if results seem discordant with other histopathologic findings."<sup>4</sup>

## References Summarized

### Health Technology Assessments

No literature identified.

### Systematic Reviews and Meta-analyses

No literature identified.

### Guidelines and Recommendations

1. National Institute for Health and Care Excellence. Early and locally advanced breast cancer: diagnosis and management. (*NICE guideline NG101*) 2018; <https://www.nice.org.uk/guidance/ng101>. Accessed 2019 Feb 5.  
*See: Section 1.6 Diagnostic assessment and adjuvant therapy planning, page 13*
2. National Institute for Health and Care Excellence. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. (*NICE guideline DG34*) 2018; <https://www.nice.org.uk/guidance/dg34>. Accessed 2019 Feb 5.
3. Holmes D, Colfry A, Czerniecki B, et al. Performance and practice guideline for the use of neoadjuvant systemic therapy in the management of breast cancer. *Ann Surg Oncol*. 2015;22(10):3184-3190.  
[PubMed: PM26224406](#)
4. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *Arch Pathol Lab Med*. 2014;138(2):241-256.  
[PubMed: PM24099077](#)

## Appendix — Further Information

### Previous CADTH Reports

5. Oncotype DX in women and men with ER-positive, HER2-negative early stage breast cancer who are lymph node negative: a review of clinical effectiveness and guidelines. (*CADTH Rapid response report: summary with critical appraisal*). Ottawa (ON): CADTH; 2014: <https://cadth.ca/oncotype-dx-women-and-men-er-positive-her2-negative-early-stage-breast-cancer-who-are-lymph-node-0>. Accessed 2019 Feb 5.

### Clinical Practice Guidelines

#### *Unspecified Methodology*

6. Alberta Health Services. Adjuvant systemic therapy for early stage (lymph node negative and lymph node positive) breast cancer; 2018: <https://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-adjuvant-systemic-therapy-breast.pdf>. Accessed 2019 Feb 5.  
See: Table 2. Genomic testing for systemic therapy decision making, page 4
7. Krop I, Ismaila N, Andre F, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. *J Clin Oncol*. 2017;35(24):2838-2847.  
[PubMed: PM28692382](https://pubmed.ncbi.nlm.nih.gov/28692382/)
8. UHN Princess Margaret Cancer Centre. Princess Margaret Cancer Centre clinical practice guidelines: breast site. 2015; [https://www.uhn.ca/PrincessMargaret/Health\\_Professionals/Programs\\_Departments/Breast/Documents/CPG\\_Breast\\_BreastCancer.pdf](https://www.uhn.ca/PrincessMargaret/Health_Professionals/Programs_Departments/Breast/Documents/CPG_Breast_BreastCancer.pdf). Accessed 2019 Feb 5.  
See *estrogen receptor (ER), progesterone receptor (PR), HER2 testing page 23*.
9. Eastern Health Breast Site Disease Group. Molecular biomarker discordance between primary and recurrent/metastatic breast cancer; 2014. <http://cancercare.easternhealth.ca/wp-content/plugins/download-attachments/includes/download.php?id=6735>. Accessed 2019 Feb 5.

#### *Consensus Statements*

10. Cardoso F, Senkus E, Costa A, et al. 4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4). *Ann Oncol*. 2018; 29: 1634–1657.  
[PubMed: PM30032243](https://pubmed.ncbi.nlm.nih.gov/30032243/)
11. Colomer R, Aranda-Lopez I, Albanell J, et al. Biomarkers in breast cancer: a consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. *Clin Transl Oncol*. 2018;20(7):815-826.  
[PubMed: PM29273958](https://pubmed.ncbi.nlm.nih.gov/29273958/)
12. CancerCare Manitoba Breast Disease Site Group. Provincial consensus recommendations for adjuvant systemic therapy for breast cancer; 2017. [https://www.cancercare.mb.ca/export/sites/default/For-Health-Professionals/galleries/files/treatment-guidelines-rro-files/practice-guidelines/breast/Adjuvant\\_Breast\\_Guideline\\_July\\_2017.pdf](https://www.cancercare.mb.ca/export/sites/default/For-Health-Professionals/galleries/files/treatment-guidelines-rro-files/practice-guidelines/breast/Adjuvant_Breast_Guideline_July_2017.pdf). Accessed 2019 Feb 5.

## Review Articles

13. Ballinger TJ, Sanders ME, Abramson VG. Current HER2 testing recommendations and clinical relevance as a predictor of response to targeted therapy. *Clin Breast Cancer*. 2015;15(3):171-180.  
[PubMed: PM25516402](#)
14. Bethune GC, Veldhuijzen van Zanten D, MacIntosh RF, et al. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization. *Histopathology*. 2015;67(6):880-887.  
[PubMed: PM25913507](#)

## Additional References

15. Biomarker-based tests for the decision for or against adjuvant systemic chemotherapy in primary breast cancer – addendum to Commission D14-01. Cologne (DE): Institute for Quality and Efficiency in Health Care; 2016. [https://www.iqwig.de/download/D18-01\\_Biomarkers-in-breast-cancer\\_Executive-summary-of-addendum\\_V1-1.pdf](https://www.iqwig.de/download/D18-01_Biomarkers-in-breast-cancer_Executive-summary-of-addendum_V1-1.pdf). Accessed 2019 Feb 5.
16. Cimino-Matthews A, Park BH, Emens LA, Tsangaris TN. 'Smarter' ordering of breast biomarker tests could save millions in health care dollars, study reveals. *Johns Hopkins Medicine*; 2015:  
[https://www.hopkinsmedicine.org/news/media/releases/smarter\\_ordering\\_of\\_breast\\_biomarker\\_tests\\_could\\_save\\_millions\\_in\\_health\\_care\\_dollars\\_study\\_reveals](https://www.hopkinsmedicine.org/news/media/releases/smarter_ordering_of_breast_biomarker_tests_could_save_millions_in_health_care_dollars_study_reveals). Accessed 2019 Feb 5.